Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03572764 · ClinicalTrials.gov registry record · Phase 1
CPX-351 (Vyxeos™) for Transplant Eligible, Higher Risk Patients With Myelodysplastic Syndrome
A Phase 1 study of Myelodysplastic Syndromes, sponsored by Washington University School of Medicine.
- Active
- Registry status
- Phase 1
- Development phase
- 20
- Enrollment target
- 3
- Study locations
NCT03572764 is a Phase 1 study of Myelodysplastic Syndromes that is active but no longer recruiting, run by Washington University School of Medicine. The registered enrollment target is 20 participants, below the 285-participant average among 173 other Myelodysplastic Syndromes trials with a reported enrollment target (93% lower). The trial reports 3 study locations across 3 states.
The verdict
NCT03572764, a Phase 1 study of Myelodysplastic Syndromes, is active but no longer recruiting, sponsored by Washington University School of Medicine.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 20 participants
- Enrollment target
- 3
- Study locations
Study Summary
This is a pilot and feasibility study of transplant eligible, higher risk myelodysplastic syndrome (MDS) patients to determine the safety and tolerability of a lower -dose and higher-dose CPX-351 regimen, with secondary objectives including complete remission (CR) rates and proportion of patients proceeding to transplant.
Conditions Studied
Interventions
- DRUG CPX-351
- PROCEDURE Research blood draw
- PROCEDURE Research skin biopsy
- PROCEDURE Research bone marrow aspirate
Study Locations (3)
Florida
- Moffitt Cancer Center - Tampa
Missouri
- Washington University School of Medicine - St Louis
Washington
- Fred Hutchinson Cancer Research Center - Seattle
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2018-12-14 |
| Est. Completion | 2027-03-25 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03572764
The ClinicalTrials.gov registry entry for NCT03572764 describes a study currently listed as active not recruiting, categorized as Phase 1. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 285-participant average among 173 other Myelodysplastic Syndromes trials with a reported enrollment target (93% lower). The listed sponsor is Washington University School of Medicine, which has 1,502 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Myelodysplastic Syndromes appearing as the primary indexed condition, and to 4 interventions - of which CPX-351 is the first listed.
NCT03572764 reports 3 study locations spanning 3 distinct geographic areas - top geographies include Florida, Missouri, Washington.
Frequently Asked Questions
What is clinical trial NCT03572764 about?
NCT03572764 is a clinical study titled "CPX-351 (Vyxeos™) for Transplant Eligible, Higher Risk Patients With Myelodysplastic Syndrome". This is a pilot and feasibility study of transplant eligible, higher risk myelodysplastic syndrome (MDS) patients to determine the safety and tolerability of a lower -dose and higher-dose CPX-351 regimen, with secondary objectives including complete remission (CR) rates and proportion of patients pr...
What is the current status of trial NCT03572764?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 20 participants. The study started on 2018-12-14. Estimated completion is 2027-03-25.
What conditions does trial NCT03572764 study?
This clinical trial studies the following conditions: Myelodysplastic Syndromes.
What interventions are being tested in trial NCT03572764?
The interventions under investigation include: CPX-351 (DRUG), Research blood draw (PROCEDURE), Research skin biopsy (PROCEDURE), Research bone marrow aspirate (PROCEDURE).
Who is sponsoring clinical trial NCT03572764?
This trial is sponsored by Washington University School of Medicine, which has 1,502 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03572764 being conducted?
This trial has 3 study locations across Florida, Missouri, Washington. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Myelodysplastic Syndromes
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Phase 1 Study of Orca-Q in Recipients Undergoing Allogeneic Transplantation for Hematologic Malignancies
RECRUITING · Phase 1
-
UAB 2419-CD34 Selection Using the Automated CliniMACS Prodigy
RECRUITING · Phase 1
-
A Study of TSC-100 and TSC-101 in AML, ALL and MDS in Patients Undergoing Allogeneic Peripheral Blood Stem Transplantation
RECRUITING · Phase 1
-
HM2023-05: GTB-3650 Trike for High Risk MDS and R/R AML
RECRUITING · Phase 1
-
A Study of GLB-001 in Patients With Relapsed or Refractory Acute Myeloid Leukemia or Relapsed or Refractory Higher Risk Myelodysplastic Syndromes
RECRUITING · Phase 1
-
Study of DISC-0974 (RALLY-MF) in Participants With Myelofibrosis or Myelodysplastic Syndrome and Anemia
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.